This study will evaluate naltrexone and cognitive-behavioral therapy treatments for alcohol
dependence and post-traumatic stress disorder (PTSD). Subjects will be randomly assigned a
6-month treatment of either: 1) naltrexone alone, 2) naltrexone with PTSD psychosocial
therapy, 3) a placebo with PTSD psychosocial therapy, or 4) placebo alone. An enhanced
medication management intervention will accompany all treatment conditions. Follow-up
assessments will be completed at 9 and 12 months after treatment.
- Meets criteria for alcohol dependence and post-traumatic stress disorder.
- Heavy drinking in the past 30 days (an average of more than 12 alcohol drinks per
week with at least 1 day of 4 or more drinks).
- Successfully complete medical detoxification.
- Exhibit clinically significant trauma-related symptoms.
- Live in a commutable distance to the University of Pennsylvania and agree to
- Aged between 18 and 65 years old.
- Able to provide an informed consent.
- Speak and read English.
- Current diagnosis of any substance dependence other than alcohol, nicotine, or
- Evidence of opiate use in the past 30 days.
- Significant risk of violence or history of serious violent behavior during the past
- Continued contact with an intimate partner if assault by the partner is the index
- Changes in dosage or medication for any SSRI treatment in the three months prior to
entering the study.
- Unstable or serious medical illness.
- Current severe psychiatric symptom.
- Mental retardation or another pervasive developmental disorder.
- Use of an investigational medication in the past 30 days.
- Pregnant, nursing or not using reliable contraception.